Carbonic anhydrase inhibitors. Selective inhibition of human tumor-associated isozymes IX and XII and cytosolic isozymes I and II with some substituted-2-mercapto-benzenesulfonamides

References

• Supuran CT, Scozzafava A, Conway J. Carbonic anhydrase. Its inhibitors and activators. CRC Press, London 2004
   Google Scholar
• Kivela AJ, Kivela J, Saarnio J, Parkkila S. Carbonic anhydrases in normal gastrointestinal tract and gastrointestinal tumours. World J Gastroenterol. 2005; 11: 155–163
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003; 23: 146–189
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Exp Opin Ther Patents 2000; 10: 575–600
   Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: Catalytic and inhibition mechanisms, distribution and physiological roles. carbonic anhyrdase. Its inhibitors and activators. London, CRC Press 2004; 1–23
   Google Scholar
• Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: Current state of the art, therapeutic applications and future prospects. J Enz Inhib Med Chem 2004; 19: 199–229
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Mastrolorenzo A, Supuran CT. Modulation of carbonic anhydrase activity and its applications in therapy. Expert Opin Ther Pat 2004; 14: 667–702
   Web of Science ®Google Scholar
• Pastoreková S, Pastorek J. Cancer-related carbonic anhydrase isozymes and their inhibition. Carbonic anhydrase. Its inhibitors and activators. CRC Press, London 2004; 255–281
   Google Scholar
• Hentunen TA, Härkönen PL, Väänänen HK. Carbonic anhydrases in calcified tissues. The carbonic anhydrases new horizons. Birkäuser Verlag, Basel, Boston, Berlin 2000; 491–497
   Google Scholar
• Pastorekova S, Zavadova Z, Kostal M, Babusikova O, Zavada J. A novel quasi-viral agent, MaTu, is a two-component system. Virology 1992; 187: 620–626
   PubMed Web of Science ®Google Scholar
• Zavada J, Zavadova Z, Pastorekova S, Ciampor F, Pastorek J, Zelnik V. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer 1993; 54: 268–274
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, Harris AL. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001; 61: 7992–7998
   PubMed Web of Science ®Google Scholar
• Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, Harris AL. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 2001; 19: 3660–3668
   PubMed Web of Science ®Google Scholar
• Zavada J, Zavadova Z, Pastorek J, Biesova Z, Jezek J, Velek J. Human tumour-associated cell adhesion protein MN/CA IX: Identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer 2000; 82: 1808–1813
   PubMed Web of Science ®Google Scholar
• Stubbs M, McSheehy PM, Griffiths JR, Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today 2000; 6: 15–19
   PubMedGoogle Scholar
• Xu L, Fidler IJ. Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells. Cancer Res. 2000; 60: 4610–4616
   PubMed Web of Science ®Google Scholar
• Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 2001; 61: 6020–6024
   PubMed Web of Science ®Google Scholar
• Kato Y, Nakayama Y, Umeda M, Miyazaki K. Induction of 103-kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines. J Biol Chem 1992; 267: 11424–11430
   PubMed Web of Science ®Google Scholar
• Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the tumor microenvironment. Cancer Res 1996; 56: 5754–5757
   PubMed Web of Science ®Google Scholar
• Helmlinger G, Endo M, Ferrara N, Hlatky L, Jain RK. Formation of endothelial cell networks. Nature 2000; 405: 139–141
   PubMed Web of Science ®Google Scholar
• Ivanov SV, Kuzmin I, Wei MH, Pack S, Geil L, Johnson BE, Stanbridge EJ, Lerman MI. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci U.S.A 1998; 95: 12596–12601
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60: 7075–7083
   PubMed Web of Science ®Google Scholar
• Svastova E, Hulikova A, Rafajova M, Zat'ovicova M, Gibadulinova A, Casini A, Cecchi A, Scozzafava A, Supuran CT, Pastorek J, Pastorekova S. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004; 577: 439–445
   PubMed Web of Science ®Google Scholar
• Teicher BA, Liu SD, Liu JT, Holden SA, Herman TS. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res 1993; 13: 1549–1556
   PubMed Web of Science ®Google Scholar
• Vukovic V, Tannock IF. Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br J Cancer 1997; 75: 1167–1172
   PubMed Web of Science ®Google Scholar
• Supuran CT, Casini A, Scozzafava A. Development of carbonic anhydrase inhibitors. Carbonic anhyrdase. Its inhibitors and activators. CRC Press, London 2004; 67–147
   Google Scholar
• Pastorekova S, Casini A, Scozzafava A, Vullo D, Pastorek J, Supuran CT. Carbonic anhydrase inhibitors: The first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg Med Chem Lett 2004; 14: 869–873
   PubMed Web of Science ®Google Scholar
• Vullo D, Innocenti A, Nishimori I, Pastorek J, Scozzafava A, Pastorekova S, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?. Bioorg Med Chem Lett 2005; 15: 963–969
   PubMed Web of Science ®Google Scholar
• Cecchi A, Hulikova A, Pastorek J, Pastorekova S, Scozzafava A, Winum J-Y, Montero J-L, Supuran CT. Carbonic anhydrase inhibitors. Sulfonamides inhibit isozyme IX mediated acidification of hypoxic tumors. Fluorescent sulfonamides design as probes of membrane-bound carbonic anhydrase isozymes involvement in tumorigenesis. J Med Chem 2005; 48: 4834–4841
   PubMed Web of Science ®Google Scholar
• Casey JR, Morgan PE, Vullo D, Scozzafava A, Mastrolorenzo A, Supuran CT. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J Med Chem 2004; 47: 2337–2347
   PubMed Web of Science ®Google Scholar
• Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971; 246: 2561–2573
   PubMed Web of Science ®Google Scholar
• Brzozowski Z. 2-Merccapto-N-(azolyl)benzenesulfonamides I. Synthesis of N-(1,1-dioxo-1,4,2-benzodithiazin-3-yl)guanidines and their transformations into 2-mercapto-N(5-amino-1,2,4-triazol-3-yl)benzenesulfonamide derivatives with potential anti-HIV or anticancer activity. Acta Polon Pharm Drug Res 1995; 52: 91–101
   Google Scholar
• Brzozowski Z, Kornicka A. Synthesis of some 2-hydroxy-1-[(4-chloro-2-mercaptophenyl)sulfonyl]imidazole derivatives with potential anticancer activity. Acta Polon Pharm Drug Res 1999; 56: 135–142
   Google Scholar
• Pomarnacka E, Kornicka A. Synthesis of S,N-substituted 2-mercaptobenzenesulfonamide derivatives with potential pharmacological activity. Acta Polon Pharm Drug Res 1998; 55: 297–304
   Google Scholar
• Brzozowski Z. 2-Merccapto-N-(azolyl)benzenesulfonamides II. Synthesis, anti-HIV-1 and anticancer activity of some S-substituted 4-chloro-2-mercapto-5-methyl-N-(5-amino-1,2,4-triazol-3-yl)benzenesulfonamides. Acta Polon Pharm Drug Res 1995; 52: 287–292
   Google Scholar
• Brzozowski Z. Synthesis of 4-chloro-2-mercapto-5-methyl-N-(2-amino-1,3,5-triazin-4-yl)benzenesulfonamide derivatives as potential anti-HIV agents. Acta Polon Pharm Drug Res 1998; 55: 49–56
   Google Scholar
• Neamati N, Mazumder A, Sunder S, Owen JM, Schultz RJ, Pommier Y. 2-Merccaptobenzenesulfonamides as novel inhibitors of human immunodeficiency virus type 1 integrase and replication. Antiviral Chem Chemother 1997; 8: 485–494
   Google Scholar
• Brzozowski Z, Sławiński J. Synthesis of some derivatives of 3-mercapto-1,1-dioxo-1,4,2-benzodithiazine. Acta Polon Pharm 1984; 41: 133–139
   Google Scholar
• Brzozowski Z, Sławinski J. Synthesis of some derivatives of 7-carboxy-3-mercapto-1,1-dioxo-1,4,2-benzodithiazine. Acta Polon Pharm 1984; 41: 5–13
   Google Scholar
• Brzozowski Z, Sączewski F, Sanchez T, Kuo Ch-L, Gdaniec M, Neamati N. Synthesis, antiviral and anti-HIV-1 integrase activities of 3-aroyl-1,1-dioxo-1,4,2-benzodithiazines. Bioorg Med Chem 2004; 12: 3663–3672
   PubMed Web of Science ®Google Scholar